IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap.

Prakash Raman, VP and global head of BD&L at Novartis Institutes for BioMedical Research, told BioCentury the company wants to move to “earlier stages of innovation, because I think that’s where we feel that we can bring a lot more value to table for partners.”...